Drug Trial Radar · NCT06645886
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
13
Actual
Start
Dec 9, 2024
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Kumquat Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
Conditions
- Hematologic Malignancies
- Adult
Interventions
KQB198Drug
Oral KQB198
DasatinibDrug
Oral dasatinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)Time frame: 28 Days
- Recommended Phase 2 Dose (RP2D) (Part 1)Time frame: Up to 30 months
- Efficacy of study treatment and optimal biologic dose, as measured by molecular response (MR) per European Leukemia Network (ELN) 2020 Guidelines (Part 2).Time frame: Up to 6 Months
Locations
29 sites in 8 countries. Site status is shown where the registry gives one.
University of California, San Francisco (UCSF)
San Francisco, California
Colorado Blood Cancer Institute
Denver, Colorado
Moffitt Cancer Center
Tampa, Florida
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Duke University Medical Center
Durham, North Carolina
Oncology Hematology Cincinnati
Cincinnati, Ohio
Sarah Cannon Research Institute (SCRI) - Transplant and Cellular Therapy Operations
Nashville, Tennessee
Texas Oncology Austin Central
Austin, Texas
MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists
Fairfax, Virginia
AP-HM - Hopital de la Timone
Marseille, France
CHRU de Tours - Hopital Bretonneau
Tours, Centre-Val de Loire, France
Medizinische Hochschule Hannover (MHH)
Hanover, Lower Saxony, Germany
Universitaetsklinikum Jena
Jena, Thuringia, Germany
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
Bologna, Bologna, Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, Lazio, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Lombardy, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Milan, Milan, Lombardy, Italy
Stichting Radboud Universitair Medisch Centrum
Nijmegen, Gelderland, Netherlands
Aidport Sp. z o.o.
Poznan, Greater Poland Voivodeship, Poland
Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii
Gdansk, Pomeranian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii
Gdansk, Pomeranian Voivodeship, Poland
Pratia Onkologia Katowice
Katowice, Silesian Voivodeship, Poland
Hospital Regional Universitario de Malaga
Málaga, Andalusia, Spain
Institut Catala d'Oncologia - L'Hospitalet
L'Hospitalet de Llobregat, Catalonia, Spain
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain
Hospital Universitario La Paz
Madrid, Madrid, Spain
Hammersmith Hospital
London, Greater London, United Kingdom
Nottingham University Hospitals
Nottingham, Nottinghamshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.